Spin-off - Embecta Corp.

Add to your watchlist
Back to List of Spin Offs

Form Type: 10-Q

Filing Date: 2025-02-06

Corporate Action: Spin-off

Type: Update

Accession Number: 000187278925000006

Filing Summary: Embecta Corp. filed a quarterly report for the period ending December 31, 2024, detailing financial performance and operations after its spin-off from Becton, Dickinson and Company. The report highlights key metrics, including revenues of $261.9 million, a decrease from $277.3 million in the prior year, and a net income of $0, compared to $20.1 million in the previous year. The company's gross profit declined to $157.1 million, impacted by increased cost of products sold and operating expenses totaling $128.4 million. Operating income was $28.7 million, significantly lower than the $45.5 million reported a year earlier. The report also outlines changes in assets and liabilities, including a total assets figure of $1,149.5 million and total liabilities of $1,918.3 million, resulting in an equity position of $(768.8) million. Additionally, the quarterly financials reflect costs related to a restructuring plan as the company moves away from its patch pump program, with an expected total restructuring cost between $35 million and $45 million. Restructuring activities and the implications of the separation from BD are noted, highlighting ongoing transitions in operations and financial management.

Additional details:

Shares Outstanding: 58134434


Total Assets: 1149.5


Total Liabilities: 1918.3


Total Equity: -768.8


Operating Income: 28.7


Net Income: 0


Revenue: 261.9


Form Type: 8-K

Filing Date: 2024-03-28

Corporate Action: Spin-off

Type: New

Accession Number: 000187278924000010

Filing Summary: This document concerns a spin-off as it discusses agreements related to the transition services established during the spin-off of the diabetes care business from BD to Embecta.

Additional details:

Newco Cik: 1872789

Parent Cik: 1872789

File Number: 001-41186

:

Effective Date: 2024-03-28

Comments

No comments yet. Be the first to comment!